ClinicalTrials.gg
CompletedNCT04335604Updated Jun 3, 2022

A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

A Phase 1 interventional study of JPI-547 in Advanced Solid Tumors, sponsored by Onconic Therapeutics Inc.. Completed at 2 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-06-03.

Sponsored by Onconic Therapeutics Inc. (part of Jeil Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Study summary

To assess the Safety, Tolerability, and Pharmacokinetic-pharmacodynamic Profile and efficacy of JPI-547 in patients with advanced solid tumor.

Read the detailed description

This is an open-label, Phase 1 dose escalation and expansion study of NOV140201 (JPI-547) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and the anti-tumor efficacy of JPI-547 in patients with advanced solid tumors after failure of standard of care.

Patients will be enrolled in two stages: a dose-escalation stage and an expansion phase. DLTs will be assessed as the primary endpoint in this trial.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Onconic Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients aged 19 years old or above
  • Patients that are or cytologically confirmed advanced solid tumors and are to or are able to receive standard of care
  • (ECOG) performance status 0 or 1
  • ≥12 weeks
  • Individuals who volunteer to give to the written consent to the participation after listening to sufficient explanation for this clinical study

Exclusion criteria

Exclusion Criteria:

  • History of severe drug or hypersensitivity to IP or similar class
  • Patients who have the confirmed medical history or surgery/procedure history as the followings:

    1. History of major surgery requiring general anesthesia or assisted respiration within 4 weeks prior to baseline (within 2 weeks for video-assisted thoracoscopic surgery (VATS) or open-and-closed (ONC) surgery)
    2. Severe cardiovascular disease (eg. myocardial infarction or unstable angina pectoris) within 24 weeks prior to baseline
    3. Class III or IV heart failure within 24 weeks prior to baseline
    4. Severe cerebrovascular disease within 24 weeks prior to baseline
    5. Pulmonary artery thrombosis, deep vein thrombosis, or clinically severe pulmonary disease within 24 weeks prior to baseline
    6. Infection requiring the administration of systemic antibiotics, antivirals or other uncontrolled Grade ≥3 Active infectious disease within 2 weeks prior to baseline
    7. Symptomatic interstitial lung disease
    8. Poor recovery from hematologic toxicities in previous anticancer treatment (eg. >4 weeks of Grade 3≥ toxicities)
    9. Individuals who receive bone marrow or stem cell transplant with a high dose of chemotherapy
  • Individuals as accompanied by the following diseases:

    1. Hematologic other than lymphoma
    2. History of myelodysplastic syndrome (MDS) or pre-treatment cytogenetic test results indicative of the risk of MDS/acute myelocytic leukemia (AML)
    3. Patients with symptomatic with or uncontrolled central nervous system (CNS) or (other than patients who discontinued the administration of systematic at least 4 weeks prior to baseline and who are radiologically and neurologically stable for ≥4 weeks)
    4. Patients with clinically significant abnormalities in the judgment of the investigator according to findings
    5. Uncontrolled hypertension (systolic blood pressure>140mmHg or diastolic blood pressure >90mmHg)
    6. Bleeding diatheses
    7. History of active or C virus (hepatitis patients acceptable if HBV DNA and are \<institutional lower limits)
    8. positive known (HIV)infection
    9. Severe neurological disorder and mental illness that may affect the study results in the opinion of the investigator
  • Individuals who have the following medication history:

    1. Individuals with medication history of PARP inhibitors or TNK inhibitors (This applies only to Part 2.)
    2. Individuals receiving chemotherapy, biological therapy, retinoid therapy, immunotherapy, hormone therapy or therapeutic/palliative radiotherapy for the treatment of advanced solid tumors within 4 weeks prior to baseline (except for the individuals who received nitrosourea or mitomycin within 6 weeks prior to baseline and biological target antibody within 6 weeks prior to baseline)
    3. Patients requiring the continuous administration of non-steroidal anti-inflammatory drug (NSAID) with a high bleeding risk
    4. Patients requiring continuous administration of systemic corticosteroid equivalent to Prednisone >10 mg/day
    5. Individuals who received antithrombotics, including antiplatelets and anticoagulants within 2 weeks of baseline, or expecting to require the administration during the clinical study (the administration of low molecular weight heparin (LMWH) is allowed for the management and prevention of venous thrombosis during the clinical study.)
    6. Individuals who start the new administration or dose change of bisphosphonate within 30 days of baseline among patients with breast cancer and prostatic cancer in a dose expansion cohort within 30 days of baseline (bisphosphonate administered stably for 30 days before baseline is allowed.)
  • Pregnant women, breastfeeding women, or female of and male who are not willing to practice abstinence or use appropriate * during the clinical study and for 3 months after the administration of the IP
  • Individuals who were administered other IPs or the device within 4 weeks prior to baseline
  • Individual considered ineligible or unavailable for this study for other reasons, in the opinion of the investigator
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    JPI-547

    Drug: JPI-547

Interventions

  • The dose levels will be escalated following a 3+3 dose escalation scheme.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT) and Maximum tolerated dose (MTD)

    subjects will be treated and observed for DLT through the end of the first cycle

    Time frame: 21days

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC) of JPI-547

    to observe pharmacokinetic parameter

    Time frame: 1 and 15 days

  2. Peak Plasma Concentration (Cmax) of JPI-547

    to observe pharmacokinetic parameter

    Time frame: 1 and 15 days

  3. Time at maximum concentration(Tmax) of JPI-547

    to observe pharmacokinetic parameter

    Time frame: 1 and 15 days

  4. Half-life of JPI-547

    to observe pharmacokinetic parameter

    Time frame: 1 and 15 days

  5. Accumulation ratio of JPI-547

    to observe pharmacokinetic parameter

    Time frame: 1 and 15 days

07

Study locations

2 sites
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
  • Seoul National University College of Medicine
    Seoul, 03080, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Dec 2021, 48 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2018
First posted
Apr 6, 2020
StartActual
Dec 6, 2017
Primary completionActual
Dec 14, 2021
CompletionActual
Dec 14, 2021
Last update
Jun 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04335604
Responsible party
Sponsor
First posted
Apr 6, 2020
Start date
Dec 6, 2017
Primary completion
Dec 14, 2021
Completion
Dec 14, 2021
Last update
Jun 3, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nesuparib

Start the discussion